D360 is used by discovery scientists in pharmaceutical organisations to provide data access and analysis capabilities including: full-featured, forms-based queries and browsing, a data access dashboard for fast access to data searches, and a range of user-requested data analysis functionality.
As per the agreement, Pfizer is expected to license to Tripos certain rights to its internally-developed discovery informatics system, RGate, and Tripos will extend capabilities within D360 to accommodate Pfizer’s requirements.
Tripos said that D360 will provide technology to Pfizer scientists, while leveraging investment in their legacy system to reduce cost and create a modern platform for drug discovery and development.
Patrick Flanagan, chief operating officer of Tripos, said: “Tripos is thrilled that Pfizer has selected D360 as the tool of choice for its worldwide discovery organisation. D360 accelerates drug discovery and development projects by increasing the ability to access, analyse, and share knowledge throughout worldwide discovery teams. Additionally, this agreement incorporates and extends the best of Pfizer’s existing RGate technology.”